Member Info for Hartlebury

London I don’t think he was promoted to director, he was appointed director of SYME Ltd (UK subsidiary) but I might be wrong

No Paul, deadline re suspension is six months, after which the share may be delisted. Wasn’t EUA suspended for five months?

PaulQ the 30 days is in relation to listing, not restoration of trading after suspension.

No there’s no date, it’s not up to us or the company. Just have to wait. On the bright side it shouldn’t stop work continuing at SYME so let’s hope there’s good news coming along with a restoration to trading soon.

Shaun P always tried to be as accurate as possible and was frequently conservative. Yes he over estimated the revenue as it turned out and has explained his reasons why (a certain interview quoting 50m tests). The possibility remains that a lot of that revenue may simply have been pushed into 2021. You are conveniently ignoring his fair value estimate of SPwith that revenue, which was around £12.50, so it seems you liked his revenue forecasts but made up your own SP on that - handy to pick and choose!

I think that would have been good alongside the TU, but right now an rns like that would come across as desperate and wouldn’t move SP up (risk moving it down!) we really need a proper operational update and news of real contracts.

*in a similar way

I did wonder about that statement Harv, I believe they were sequencing 8-10% of positives up until now and that was reported as world beating levels, it seems like an extraordinary leap to 100% within any useful timeframe, SNPsig appears invaluable and surely DHSC would want to ensure supplies for UK I’m a similar way to vaccine orders!

I understand that institutions now hold approx 8% of NCYT, which I believe is quite an increase - please can anyone confirm how this compares to a month ago?

Do you think the new LFT’s will get close to PCR for s&s Wbernard? If not, I’m thinking that would be a reason why Microgen don’t appear to have pursued the production of one?

Thanks..one more question, on RUO would you know if that would mean it could be in use now for the surge testing?

So was the conclusion on the establishment of Syme Ltd just that it’s a placeholder to protect the name from others using it?

Thanks Wbernard too!

Thank you James, great to get a post from someone knowledgable! Would you agree that if possible it would be best to use the new assays as extensively as possible as part of general tracking to identify outbreaks of specific variants? Also, given the speed at which this new test has been developed, presumably it would be easy to adapt to add other variants as they emerge?

How can a share be corrupt?

Ah, sorry!

Wolf he’s not a board director, he is Head of Enterprise Risk Management at SYME plc and a director of SYME Ltd, that’s why no rns

We know that they are testing patients with PCR before any procedures..Wilson can confirm this from personal experience.

Quite Donno - they didn’t seem inclined to flip the LFT coin in that situation!

They are Oriens...and they are also getting confirmatory PCR. PCR won’t be going anywhere in clinical settings. And it seems clear to me that a top priority for the government will be to carefully track variants in case of outbreaks. Sequencing will still be required on a proportion of positive tests in case of further new variants but if I were in charge of testing I would be using the new assay as often as possible (worldwide not just here.